July 18- Shares of Trupanion Inc rose as much as 15 percent in their market debut, valuing the pet insurer at $304 million, as investors bet on growing demand among pet owners to insure their cats and dogs.» Read More
The gloves are off. Overnight, Pfizer came out with a new study on the world's top-selling drug, Lipitor, for cholesterol. The company says if you switch from its drug to generic Zocor you've got a 30% greater chance of dying from a heart attack, stroke or some other "major cardiovascular" event.
Mortgage insurer MGIC Investment and bond insurer Radian Group agreed to terminate their pending merger, the companies said Wednesday, citing market conditions.
Swiss Life's first-half net profit rose 21%, comfortably beating expectations, and the insurer said on Tuesday it would set new financial goals in December.
British insurer Standard Life beat forecasts on Tuesday with a 71%t rise in first-half operating profit, boosted by growth in its key domestic market and increased sales of highermargin products.
Norwegian financial group Storebrand on Monday announced a deal to buy Sweden's Handelsbanken's insurance and pensions subsidiary SSP for 18 billion Swedish kronor (1.9 billion euros; $2.65 billion), creating the Nordic region's leading life insurance and pensions provider.
The state of Ohio has filed an anti-trust lawsuit accusing Marsh & McLennan, AIG and three other insurers and their subsidiaries of price fixing and other anti-competitive behavior, Attorney General Marc Dann said on Monday.
Shares of Neurochem today are trading at a new low after the Canadian biotech announced its developmental drug for Alzheimer's didn't work well enough. It is the latest evidence that cracking the code of this complex disease is extremely challenging. We recently did a story on the drug called Alzhemed, the potential AD-drug market and other companies working on treatments/cures at a dementia conference in Washington, DC.
Two years after hurricanes Katrina and Rita swamped New Orleans, the recovery efforts have created a tale of two cities … and it is doubtful that the full grandeur of the old Crescent City will ever arise from either one of them.
Novo Nordisk, the world's biggest diabetes drug company, is very lightly traded on the New York Stock Exchange, but check out the move in the stock today. Coincidentally, on the day that The New York Times runs a front-page story (with two jump pages) on how controlling diabetes is about lowering blood sugar and cholesterol levels, the Danish drugmaker is out with major data on its glucose fighting drug Liraglutide.
QBE Insurance Group, Australia's top insurer by premium income, reported a higher-than-expected first-half profit on U.S. acquisitions, and upgraded its insurance profit forecast.
Two things have happened recently that made me realize we are at the "tipping point" of environmental awareness. One is that my company began implementing some green initiatives - a company whose rubbish bins were often filled with styrofoam cups and lunch boxes and where dozens of television and computer monitors used to hum ceaselessly overnight. The other is that Live Earth was a total flop audience-wise. Not because people were unaware of the need to protect the environment, but because everyone, including people like me, had already heard enough about it. Eighteen years after Time magazine put "Endangered Earth" on its cover, yeah, we do finally get it.
Ping An Insurance, China's second-largest life insurer, posted a 140% gain in first-half profit late on Thursday, driven by a contribution from its banking operations and strong investment returns amid a booming domestic stock market.
Net profit at insurer Zurich Financial Services surged 33% in the first half of the year, beating market expectations despite heavy flooding in the U.K., the company reported Thursday.
BioMedTracker, which monitors drug development for investors, ran some numbers for me. As of August 13th, how does the number of FDA-approved drugs and "approvable" drugs compare to the same period a year ago? According to the company, drug approvals are down 16% and approvable letters are up 55%. An approvable letter is what the FDA issues when it believes it might someday okay a drug, but only if a company provides additional -- often publicly unspecified -- data. So, for investors, "approvable" is a euphemism for delay.
While the rest of the market is struggling with liquidity issues, at least one sector isn't having trouble generating cash.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Bryan Gaffin, VP, Group Creative Director at G2 Direct & Digital writes to say that his division and not G2 Branding & Design is responsible for the new Pfizer website. They're part of the same company, WPP Group, but separate divisions. Credit where credit is due.
Dutch insurer Aegon said has agreed to buy Merrill Lynch Life Insurance and ML Life Insurance of New York for $1.3 billion in cash to boost its sales of variable annuities and distribution in the United States.
Burlington Northern shares are picking up speed on Wall Street, after Warren Buffett added to his bet on the railroad. Buffett's apparent optimism on the rails gives Fast Money's Guy Adami an idea. PLUS: Why Geico's Gecko may be going back to Massachusetts.
Insurance broker Marsh & McLennan said Tuesday quarterly earnings edged higher on revenue growth but missed forecasts, as operating expenses not related to compensation and benefits rose.
Second-quarter net profit at Swiss Re rose by 45%, in line with expectations, and the reinsurer said on Tuesday it saw a strong outlook for the rest of the year.
Get the best of CNBC in your inbox